Sex: M
Vaccine: COVID19
Symptoms: Hypoglycaemia, Muscular weakness, Myalgia, Nausea, Neuropathy peripheral
Clinical narrative: Multiple Myeloma/diagnosed INGUS which is one of the indicators for multiple myeloma.; Glaucoma got worst; Mild neuropathy on the legs/it's mild and shouldn't cause the continuous weakness; Difficulty walking; Still has extreme weakness in the legs; Joint pain; Muscle pains; Extreme fatigue; Severe weakness/continuous weakness; Hypoglycemia; Nauseated; Serious side effects; This spontaneous case was reported by a consumer and describes the occurrence of PLASMA CELL MYELOMA, GLAUCOMA, and NEUROPATHY PERIPHERAL in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008B21A and 011A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypoglycemia, High cholesterol, and Glaucoma. Concomitant products included LATANOPROST for Glaucoma, PRAVASTATIN for High cholesterol, ASPIRIN, VITAMIN D, SIMBRINZA, and MULTIPLE VITAMINS for an unknown indication.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced VACCINATION COMPLICATION (Serious side effects). On 30-Mar-2021, the patient experienced NAUSEA. On 31-Mar-2021, the patient experienced HYPOGLYCAEMIA, ASTHENIA, and FATIGUE. On an unknown date, the patient experienced PLASMA CELL MYELOMA (seriousness criterion medically significant), GLAUCOMA (seriousness criterion medically significant), NEUROPATHY PERIPHERAL (seriousness criterion medically significant), GAIT DISTURBANCE, MUSCULAR WEAKNESS, ARTHRALGIA, and MYALGIA. In May 2021, FATIGUE and NAUSEA had resolved. At the time of the report, PLASMA CELL MYELOMA, NEUROPATHY PERIPHERAL, HYPOGLYCAEMIA, GAIT DISTURBANCE, VACCINATION COMPLICATION, ASTHENIA, ARTHRALGIA, and MYALGIA outcome was unknown and GLAUCOMA and MUSCULAR WEAKNESS had not resolved.            Concomitant medication given as Lovage 2g twice a day. Treatment information was not provided.  The patient said that nothing occur after the first dose.   The patient reported that he went to several specialist and that a Neurologist diagnosed the patient with a mild neuropathy on the legs.     The patient was sent also to an oncology and was diagnosed with multiple Myeloma, have to watch it because it might never occur but sometimes it does. The patient then said it was diagnosed INGUS which is one of the indicators for multiple myeloma.   Patient is hesitant to receive the booster dose.  Temporary report number 666967  Company Comment: This case concerns a patient with no previous relevant medical history, who experienced the unexpected events of plasma cell myeloma, glaucoma, neuropathy peripheral. The events occurred after the second dose of mRNA-1273 (Moderna COVID-19 Vaccine). The rechallenge was not applicable since events occurred after second dose. The medical history of sulfonamide remains a confounder. The benefit-risk relationship of mRNA-1273 (Moderna COVID-19 Vaccine) is not affected by this report.